- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05033223
Psycho-traumatic Consequences of the COVID-19 Health Crisis Among Professionals in Emergency Services (COVER PRO LT)
26. januar 2022 oppdatert av: Elisa Letellier, Hospices Civils de Lyon
Psycho-traumatic Consequences of the COVID-19 Health Crisis Among Professionals in Emergency Services and SAMU: Multicenter Cohort Study (COVid in EmeRgency PROfessionnals Long Term)
The COVID-19 outbreak has been categorized as a pandemic and declared an international public health emergency by WHO.
In this context, an exceptional mobilization and a complete reorganization of the organization of the healthcare offer was put in place.The investigators will study the psychological consequences among emergency department (ED) / SAMU (Service d'Aide Médicale Urgente) professionals exposed during the COVID-19 pandemic to high psychological stress due to work overload, changes in practices and fears of contamination.They will evaluate at 9 and 12 months after the end of the second lockdown (July December 2020), post-traumatic stress disorder (PTSD), personal and professional stress, anxiety and depression, burn-out and consumption of anxiolytic products.
This is a multi-center study and includes doctors, DE interns and nurses, other paramedics and medical regulatory assistants working in one of the ED or SAMU working during phase 3 of the COVID-19 pandemic.
It should make it possible to know the psychological load of the months following the epidemic among health professionals who worked in emergencies during this period and to understand their risk of occurrence of PTSD.
These elements are also essential to improve the management of health crises and to put in place preventive measures for health professionals, in particular in anticipation of recurrences, second wave or future new episode.
Studieoversikt
Status
Fullført
Forhold
Studietype
Intervensjonell
Registrering (Faktiske)
71
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Pierre-Bénite, Frankrike, 69310
- Service d'Accueil des Urgences
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Adults
- Administrative and technical medical staff of the Hospices Civils de Lyon
- Contractual or holder
- Having participated in the COVER PRO study
- Working in one of the HCL phase 3 departments of the COVID-19 pandemic.
- Affiliated with a social security system
- Having signed an informed consent
Exclusion Criteria:
- Refusal to participate
- Major under legal protection
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Follow-up
|
PCL-5 autoquestionnaire to make the PTSD diagnosis
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Existence of a Post Traumatic Stress Disorder (PTSD) at 12 months using PTSD Scale
Tidsramme: 12 months after the end of the second Lockdown (December 2020)
|
: Existence of a PTSD after the end of the second lockdown using the PCL-5 scale (Post Traumatic Stress Disorder Checklist, 20 items, self-questionnaire) validated in French for PTSD screening.
The presence of a "probable PTSD" will be defined by a cut-off score of 31/80 and at least a positive response to one of the four questions asking if the symptoms were causing difficulties in relations with family, friends, work or in daily life
|
12 months after the end of the second Lockdown (December 2020)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Existence of a Post Ttraumatic Stress Disorder (PTSD) 9 months using PTSD Scale
Tidsramme: 9months after the end of the second Lockdown (December 2020)
|
Existence of a PTSD after the end of the second lockdown using the PCL-5 scale (Post Traumatic Stress Disorder Checklist, 20 items, self-questionnaire) validated in French for PTSD screening.
The presence of a "probable PTSD" will be defined by a cut-off score of 31/80 and at least a positive response to one of the four questions asking if the symptoms were causing difficulties in relations with family, friends, work or in daily life
|
9months after the end of the second Lockdown (December 2020)
|
|
Anxiety evaluation at 12 months using HAD scale
Tidsramme: 12months after the end of the second Lockdown (December 2020)
|
Existence of anxious symptomatology assessed by the HAD scale.
14 items, cut-off score: 8 suspected disorder, 11: proven disorder
|
12months after the end of the second Lockdown (December 2020)
|
|
Anxiety evaluation at 9 months using HAD scale
Tidsramme: 9months after the end of the second Lockdown (December 2020)
|
Existence of anxious symptomatology assessed by the HAD scale.
14 items, cut-off score: 8 suspected disorder, 11: proven disorder
|
9months after the end of the second Lockdown (December 2020)
|
|
Depression evaluation at 12 months using HAD scale
Tidsramme: 12months after the end of the second Lockdown (December 2020)
|
Existence of depression symptomatology assessed by the HAD scale.
14 items, cut-off score: 8 suspected disorder, 11: proven disorder
|
12months after the end of the second Lockdown (December 2020)
|
|
Depression evaluation at 9 months using HAD scale
Tidsramme: 9months after the end of the second Lockdown (December 2020)
|
Existence of depression symptomatology assessed by the HAD scale.
14 items, cut-off score: 8 suspected disorder, 11: proven disorder
|
9months after the end of the second Lockdown (December 2020)
|
|
Presence of a Burn out at 12 months using the Maslach Burnot Inventory (MBI) scale
Tidsramme: 12months after the end of the second Lockdown (December 2020)
|
Burnout characterized by the Maslach burnout inventory scale.
All MBI items are scored using a 7 level frequency ratings from "never" to "daily."
The MBI has three component scales: emotional exhaustion (9 items), depersonalization (5 items) and personal achievement (8 items).
Each scale measures its own unique dimension of burnout.
|
12months after the end of the second Lockdown (December 2020)
|
|
Presence of a Burn out at 9 months using the MBI scale
Tidsramme: 9months after the end of the second Lockdown (December 2020)
|
Burnout characterized by the Maslach burnout inventory scale.
All MBI items are scored using a 7 level frequency ratings from "never" to "daily."
The MBI has three component scales: emotional exhaustion (9 items), depersonalization (5 items) and personal achievement (8 items).
Each scale measures its own unique dimension of burnout.
|
9months after the end of the second Lockdown (December 2020)
|
|
Work-related stress measured using Karasek questionnaire at 12 months
Tidsramme: 12months after the end of the second Lockdown (December 2020)
|
Work-related stress measured using Karasek questionnaire at 12 months
|
12months after the end of the second Lockdown (December 2020)
|
|
Work-related stress measured using Karasek questionnaire at 9 months
Tidsramme: 9months after the end of the second Lockdown (December 2020)
|
Work-related stress measured using Karasek questionnaire at 9 months
|
9months after the end of the second Lockdown (December 2020)
|
|
Consumption of psychoactive substances at 12 months
Tidsramme: 12months after the end of the second Lockdown (December 2020)
|
Change in the consumption of psychoactive substances at 12 months
|
12months after the end of the second Lockdown (December 2020)
|
|
Percentage of patients with psychological Support at 12 months
Tidsramme: 12months after the end of the second Lockdown (December 2020)
|
Percentage of patients who benefit from a psychological support at 12 months
|
12months after the end of the second Lockdown (December 2020)
|
|
Mean number of days of sick leave at 12 months
Tidsramme: 12months after the end of the second Lockdown (December 2020)
|
Mean number of days of sick leave at 12 months
|
12months after the end of the second Lockdown (December 2020)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
12. oktober 2021
Primær fullføring (Faktiske)
16. januar 2022
Studiet fullført (Faktiske)
16. januar 2022
Datoer for studieregistrering
Først innsendt
1. september 2021
Først innsendt som oppfylte QC-kriteriene
1. september 2021
Først lagt ut (Faktiske)
2. september 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
27. januar 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
26. januar 2022
Sist bekreftet
1. januar 2022
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Psykiske lidelser
- Patologiske prosesser
- Coronavirus-infeksjoner
- Coronaviridae-infeksjoner
- Nidovirales infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Luftveisinfeksjoner
- Sykdommer i luftveiene
- Lungebetennelse, viral
- Lungebetennelse
- Lungesykdommer
- Sykdomsattributter
- Traumer og stressorerelaterte lidelser
- Covid-19
- Nødsituasjoner
- Stresslidelser, traumatiske
- Stresslidelser, posttraumatisk
Andre studie-ID-numre
- 69HCL21_0311
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .